Abstract: Beverage compositions including a steviol glycoside and an acid component are provided. The beverage has a titratable acidity of about 9 to about 11.

Abstract: Beverage products are provided which include rebaudioside A, erythritol, and an acid component. The beverage product has a titratable acidity in the range of about 8.75 to about 10.25, and a pH in the range of about 2.8 to about 3.3. Beverage products disclosed herein achieve a proper sweet/tart ratio to increase sweetness and to reduce tartness and bitterness of beverages made with natural sweeteners.

Abstract: The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

Abstract: The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

Abstract: The present invention is directed to spiropiperidine compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

Abstract: The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

Abstract: The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

Abstract: Natural beverage products and methods for making the same are disclosed. The natural beverage products comprise a non-nutritive sweetener comprising rebaudioside A, a sweetening amount of rebaudioside D, and at least one of tagatose and erythritol, and an acidulant comprising lactic acid, tartaric acid and citric acid and no phosphoric acid.

Abstract: An integrated circuit device having a selectable data rate clock data recovery (CDR) circuit and a selectable data rate transmit circuit. The CDR circuit includes a receive circuit to capture a plurality of samples of an input signal during a cycle of a first clock signal. A select circuit is coupled to the receive circuit to select, according to a receive data rate select signal, one of the plurality of samples to be a first selected sample of the input signal and another of the plurality of samples to be a second selected sample of the input signal. A phase control circuit is coupled to receive the first and second selected samples of the input signal and includes circuitry to compare the selected samples to determine whether the first clock signal leads or lags a transition of the input signal. The transmit circuit includes a serializing circuit to receive a parallel set of bits and to output the set of bits in sequence to an output driver in response to a first clock signal.

Abstract: Beverage products and methods for making the same are disclosed. The beverage products comprise a non-nutritive sweetener comprising rebaudioside A and at least one of tagatose, and erythritol, and an acidulant comprising lactic, tartaric, and citric acids.

Abstract: Without using additional probing packets, estimates of the narrow link bandwidth and available bandwidth of a network path are computed based on existing traffic. The network can be of different types such as a wireless battlefield network context or a wired or wireless commercial network environment. “Fast packets”, i.e. those packets which do not experience any queuing delay in the network, are identified. Fast packets are identified to resolve end-to-end packet delay into its constituent components (deterministic, transmission and queuing delays), estimate path utilization and eliminate the uncertainty (false alarms) that causes the prior art method to lose its effectiveness. An estimation algorithm computes end-to-end transmission delay and end-to-end deterministic delay of fast packets traveling along a path in a network. Examples of deterministic delay include satellite propagation delays and clock effects.

Abstract: The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

Abstract: The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

Abstract: The present invention is directed to compounds of formula (I) (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

Abstract: A combination of one or more non-nutritive sweeteners, a sugar alcohol and D-tagatose are included in a reduced-calorie beverage or food product to achieve a taste substantially similar to that of a full-calorie beverage or food product. The combination is suitable for use in reduced-calorie frozen carbonated beverages. Preferably, the one or more non-nutritive sweeteners include one or more steviosides, a Stevia glycoside, a derivative of a Stevia glycoside, a glycoside of steviol, or a Lo Han Guo extract.

Abstract: The present invention is directed to spiropiperidine compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

Abstract: Without using additional probing packets, estimates of the narrow link bandwidth and available bandwidth of a network path are computed based on existing traffic. The network can be of different types such as a wireless battlefield network context or a wired or wireless commercial network environment. “Fast packets”, i.e. those packets which do not experience any queuing delay in the network, are identified. Fast packets are identified to resolve end-to-end packet delay into its constituent components (deterministic, transmission and queuing delays), estimate path utilization and eliminate the uncertainty (false alarms) that causes the prior art method to lose its effectiveness. An estimation algorithm computes end-to-end transmission delay and end-to-end deterministic delay of fast packets traveling along a path in a network. Examples of deterministic delay include satellite propagation delays and clock effects.

Abstract: The present invention provides 2-aryl or heteroaryl indole derivatives which are ASIC channel modulators, maceutical compositions containing such compounds, and methods of using them as therapeutic agents.

Abstract: Without using additional probing packets, estimates of the narrow link bandwidth and available bandwidth of a network path are computed based on existing traffic. The network can be of different types such as a wireless battlefield network context or a wired or wireless commercial network environment. “Fast packets”, i.e. those packets which do not experience any queuing delay in the network, are identified. Fast packets are identified to resolve end-to-end packet delay into its constituent components (deterministic, transmission and queuing delays), estimate path utilization and eliminate the uncertainty (false alarms) that causes the prior art method to lose its effectiveness. An estimation algorithm computes end-to-end transmission delay and end-to-end deterministic delay of fast packets traveling along a path in a network. Examples of deterministic delay include satellite propagation delays and clock effects.

Abstract: In a clustered processing system, replication logic controls replication of object data to one of more replica instances. Correction logic generates correction data based on the object data and generates code words by combining the object data and the correction data. The code words are transmitted to the one or more replica instances such that correctable errors in the object data can be corrected without re-transmission of the object data.